Abstract
Purpose
To determine the minimum levels of l-asparaginase (ASNase) activity necessary to maintain l-asparagine (Asn) depletion under ASNase treatment in acute lymphoblastic leukemia (ALL).
Methods
We measured ASNase activity using an enzyme coupling method with a limit of detection of 2 U/l and examined the relationship between ASNase activity and Asn levels in blood samples from 14 children with ALL.
Results
In all but one patient showing high ASNase antibody titers, minimum ASNase activity to maintain Asn depletion levels below the limit of detection (40 ng/ml) ranged from 6 to 180 U/l with a median value of 16 U/l. In 11 patients, the enzyme activity corresponding to minimum detectable Asn levels ranged from 2 to 32 U/l with a median value of 6.5 U/l. Patients with an ASNase activity of 2 U/l or an undetectable activity (<2 U/l) had nearly normal Asn levels: 4140±1161 ng/ml at 2 U/l and 7235±3107 ng/ml at <2 U/l (mean±SD). Statistical analysis showed that ASNase activity in the range of 2–32 U/l was inversely correlated with Asn levels (r=−0.803, P=0.001).
Conclusion
These results show that Asn levels are strongly correlated with plasma ASNase activity even at low enzyme activities (<50 U/l) and that this sensitive ASNase assay can be used to estimate plasma Asn depletion levels.
Similar content being viewed by others
Abbreviations
- ALL:
-
Acute lymphoblastic leukemia
- Asn:
-
Asparagine
- ASNase:
-
Asparaginase
- SSA:
-
Sulfosalicylic acid
References
Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, Werber G, Borste H, Wurthwein G, Jurgens H, Boos J (1997) Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 96:675
Arbertsen BK, Schroder H, Ingerslev J, Jakobsen P, Avramis VI, Muller HJ, Carlsen NT, Schmiegelow K (2001) Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 115:983
Asselin BL, Lorenson MY, Whitin JC, Coppola DJ, Kende AS, Blakely RL, Cohen HJ (1991) Measurement of serumL-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res 51:6568
Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ (1993) Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11:1780
Boos J (1997) Pharmacokinetics and drug monitoring ofL-asparaginase treatment. Int J Clin Pharmacol Ther 35:96
Boos J, Werber G, Ahlke E, Schulze-Westhoff P, Nowak-Gottl U, Wurthwein G, Verspohl EJ, Ritter J, Jurgens H (1996) Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 32A:1544
Dolowy WC, Henson D, Cornet J, Sellin H (1966) Toxic and antineoplastic effects ofL-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer 19:1813
Gentile D, Zucchetti M, Conter V, Masera G, D’Incalci M (1994) Determination ofL-asparagine in biological samples in the presence of L-asparaginase. J Chromatogr B 657:47
Gentile D, Conter V, Rizzari C, Tschuemperlin B, Zucchetti M, Orlandoni D, D’Incalci M, Masera G (1996)L-asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposure to Erwinia L-asparaginase. Ann Oncol 7:725
Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, Riehm H (1991) Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 78:1166
Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW (1967)L-asparaginase therapy for leukemia and other malignant neoplasms. JAMA 202:882
Muller HJ, Boos J (1998) Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 28:97
Oettgen HF, Old LJ, Boyse EA, Campbell HA, Philips FS, Clarkson BD, Tallal L, Leeper RD, Schwartz MK, Kim JH (1967) Inhibition of leukemias in man by L-asparaginase. Cancer Res 27:2619
Pinheiro JPV, Muller HJ, Schwabe D, Gunkel M, Da Palma C, Henze G, von Schutz V, Winkelhorst M, Wurthwein G, Boos J (2001) Drug monitoring of low-dose PEG-asparaginase (OncasperTM) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol 113:115
Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG (1981) L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 41:4554
Rizzari C, Zucchetti M, Conter V, Diomed L, Bruno A, Gavazzi L, Paganini M, Sparano P, Lo Nigro L, Arico M, Milani M, D’Incalci M (2000) L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 11:189
Takatsuka S, Kitaura K, Sato K, Tsuchiya J (1998) Fundamental examination and clinical application on IgE and IgG4 antibodies specific forl-asparaginase by f-ELISA. J Med Technol 42:233
Tsukimoto I, Matsui J, Iwashita H, Shigeta K, Suzuki H, Hashimoto T (1992) Improved measurements of anti-L-asparaginase IgG antibody and its clinical applications. Jpn J Clin Hematol 33:24
Tsurusawa M, Katano N, Yamamoto Y, Hirota T, Koizumi S, Watanabe A, Takeda T, Hatae Y, Yatabe M, Mimaya J, Gushiken T, Nishi K, Anami K, Kikuta A, Kanegane H, Asami K, Nishikawa K, Sekine I, Kawano Y, Iwai A, Furuyama T, Ijichi O, Miyake M, Mugishima H, Fujimoto T (1999) Improvement in CNS protective treatment in non-high risk childhood acute lymphoblastic leukemia, a report from the Japanese Children’s Cancer and Leukemia Study Group (CCLSG). Med Pediatr Oncol 32:259
Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, Hempel G, Muller HJ, Lumkemann K, Schrappe M, Rath B, Fleischhack G, Mann G, Boos J (1999) Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 104:313
Yasui Y (1991) Application of Shimadzu amino acid analysis system to biological sciences. Shimadzu Rev 47(4):365
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsurusawa, M., Chin, M., Iwai, A. et al. l-Asparagine depletion levels and l-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment. Cancer Chemother Pharmacol 53, 204–208 (2004). https://doi.org/10.1007/s00280-003-0734-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-003-0734-5